These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 39134188)

  • 21. New Technologies Bloom Together for Bettering Cancer Drug Conjugates.
    Jin Y; Edalatian Zakeri S; Bahal R; Wiemer AJ
    Pharmacol Rev; 2022 Jul; 74(3):680-711. PubMed ID: 35710136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Payload diversification: a key step in the development of antibody-drug conjugates.
    Conilh L; Sadilkova L; Viricel W; Dumontet C
    J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
    Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Recent Developments of ADCs with the Tubulysins as the Payloads.
    Xiangrong X; Yao L; Yao A
    Mini Rev Med Chem; 2023; 23(18):1797-1805. PubMed ID: 36825713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
    Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.
    Sflakidou E; Leonidis G; Foroglou E; Siokatas C; Sarli V
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry.
    Fujii T; Matsuda Y
    Expert Opin Biol Ther; 2023; 23(11):1053-1065. PubMed ID: 37953519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.
    Bocci M; Zana A; Principi L; Lucaroni L; Prati L; Gilardoni E; Neri D; Cazzamalli S; Galbiati A
    J Control Release; 2024 Mar; 367():779-790. PubMed ID: 38346501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan: 25 years of cancer treatment.
    Bailly C
    Pharmacol Res; 2019 Oct; 148():104398. PubMed ID: 31415916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stepping forward in antibody-drug conjugate development.
    Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
    Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
    Chia CSB
    ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.